Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
December 14, 2021 09:52 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, CA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
June 09, 2021 14:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
May 17, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
SINTX Technologies announces a fabric technology shown to inactivate upon contact SARS-CoV-2, the virus causing the COVID-19 pandemic
March 09, 2021 09:00 ET
|
SINTX Technologies, Inc.
Silicon nitride-embedded fabrics proved effective against inactivating SARS-CoV-2 virusThe fabrics may be suitable for many applications, including masks, surgical gowns, and air filters ...
Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
March 09, 2021 07:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 02, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Provides Update on Influenza A Program
October 19, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...